Table 3.
Characteristics of patients placed on nasal high-frequency jet ventilation (successful versus failure groups).
| Groups, n (%) | Success, 13 (81) | Failure, 3 (19) | P-value |
|---|---|---|---|
| Birth weight, ga | 696 (548, 743) | 500 (480, 920) | 0.80 |
| Gestational age, weeksa | 24 (24, 25) | 25 (23, 26) | 0.80 |
| Postnatal age NHFJV initiated, daya | 30 (26, 45) | 37 (11, 43) | 0.90 |
| Weight when NHFJV initiated, ga | 1090 (893, 1275) | 940 (840, 1090) | 0.30 |
| Male sex, n (%) | 9 (69) | 1 (33) | 0.52 |
| Antenatal steroids, n (%) | 13 (100) | 2 (67) | 0.19 |
| Cesarean section, n (%) | 7 (54) | 2 (67) | 1.00 |
| Small for gestational age, n (%) | 3 (23) | 2 (67) | 0.21 |
| 1 min Apgara | 2 (2, 5) | 3 (3, 4) | 0.44 |
| 5 min Apgara | 6 (5, 7) | 6 (5, 7) | 0.70 |
| Surfactant administration, n (%) | 12 (92) | 3 (100) | 1.00 |
| Number of (surfactant) doses, na | 2 (2, 3) | 3 (1, 3) | 0.90 |
| Duration of NHFJV, daysa | 7 (6, 12) | 1 (1, 1) | <0.01 |
| Duration of invasive ventilation, daysa | 30 (20, 43) | 186 (8, 283) | 0.30 |
| Duration of noninvasive ventilation, daysa | 46 (42, 53) | 81 (49, 163) | 0.04 |
aMedian (25th, 75th percentile).